PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Short on time? Start with Practice-changing this week. That's where ten minutes is best spent. · PharmD Signal
112 analyses · 15 new this week · updated Jul 29
Welcome to PharmD Signal
Peer-reviewed clinical pharmacy literature, analyzed for practicing pharmacists. Set your topics to personalize.
⭐ Featured Analysis
Endocrinology / Obesity Practice-changing Grade: High

Semaglutide Cuts Cardiovascular Events in Obesity Without Diabetes

New England Journal of Medicine · Nov 11, 2023

Semaglutide cuts heart risks in obesity without diabetes.

Read Full Analysis →
New this week
Oncology PharmacyVenetoclax TDM Reduces Toxicity Risk in Posaconazole-Treated AML PatientsOncology research
Oncology PharmacyAdjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Recurrence Benefit in HCCNEJM
Critical Care / ICUSepsis survivors carry elevated psychiatric risk for five yearsCritical Care Medicine
Critical Care / ICUREDUCE-1 Pilot: Restrictive Fluids Safe But Failed Feasibility in PICUPediatric Critical Care Medicine
💊 Clinical Pearl of the Week
Targeted Therapy Evolution: From Kinase Inhibitors to Protein Degraders Oncology Pharmacy
The PROTAC hook effect means efficacy can decline at excessively high doses, a counterintuitive dose-response pharmacists should keep in mind when these agents enter practice.
⚡ Practice-changing this weekSemaglutide Cuts Cardiovascular Events in Obesity Without DiabetesSemaglutide 2.4 mg Improves Liver Histology in MASHMRI Mismatch Extends Alteplase to Unknown-Onset Stroke
Most-read this week
1EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine RecommendationsRheumatology / Immunology
2CPIC 2022 Update: CYP2C19 Genotype and Clopidogrel TherapyPharmacogenomics
3Aspirin Monotherapy Noninferior to Rivaroxaban Bridge After ArthroplastyCardiology / Anticoagulation